Drug interactions
Encorafenib + Lorlatinib
Severity: Major
Encorafenib and Lorlatinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib induces CYP3A4 and may lower lorlatinib exposure. Lorlatinib in turn can reduce encorafenib exposure, as it is mainly metabolized by CYP3A4, so efficacy of both may be reduced; lorlatinib hepatotoxicity also warrants attention.
What this interaction means in plain words
Encorafenib and Lorlatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Encorafenib belongs to Oncology; Lorlatinib belongs to Oncology.
Why it happens
Each drug induces CYP3A4, increasing the metabolism of the other.
What to do
Avoid the combination where possible. If used together, monitor ALT, AST and bilirubin and assess for reduced tumor response.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Lorlatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Lorlatinib?
MediHelp rates the interaction as major. Encorafenib and Lorlatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Encorafenib induces CYP3A4 and may lower lorlatinib exposure. Lorlatinib in turn can reduce encorafenib exposure, as it is mainly metabolized by CYP3A4, so efficacy of both may be reduced; lorlatinib hepatotoxicity also warrants attention.
How serious is the interaction between Encorafenib and Lorlatinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination where possible. If used together, monitor ALT, AST and bilirubin and assess for reduced tumor response.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
